systemic treatment Moderate to severe plaque psoriasis 2.5 6.2 candidate for IMP 24011 0 100 % systemic 2.3 5.4 treatment + need” “high subgroup Moderate to severe plaque psoriasis candidate for systemic PASI 50 treatment 20 56.7 Percentage of patients achieving 50% IMP24011 + need” 0 100 % “high reduction in baseline PASI at week 12 subgroup 12 52 ISS (all RCTs + Moderate to Mild to moderate open severe plaque ADRs dose related acute trials) % 24 41 psoriasis effects flu-like symptoms 3291 pts candidate for EU SPC 4.8
systemic treatment IMP 24011 Moderate to severe plaque psoriasis candidate for systemic treatment + “high need” subgroup 0 100 % 2.5 2.3 6.2 5.4 PASI 50 Percentage of patients achieving 50% reduction in baseline PASI at week 12 IMP24011 Moderate to severe plaque psoriasis candidate for systemic treatment + “high need” subgroup 0 100 % 20 12 56.7 52 effects ADRs Mild to moderate dose related acute flu-like symptoms ISS (all RCTs + open trials) 3291 pts EU SPC 4.8 Moderate to severe plaque psoriasis candidate for % 24 41
Download_ProACTURL_EffectsTable.docx